metastatic castration-resistant prostate (mCRPC)

  • A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer

    Published in Everyday Urology - Oncology Insights: Volume 2, Issue 2
    Everyday Urology-Oncology Insights: Volume 2, Issue 2

    Focusing on The First and Only FDA Approved Targeted  Alpha Therapy Radium-223 in the Treatment of mCRPC

    The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University as a forum for presentations on the latest developments in radiotherapy with alpha emitters in cancer. With over 200 participants the symposium covered advances in cancer treatment using alpha emitters as targeted therapy, clinical and preclinical research, radionuclide production, instrumentation and dosimetry.1
    Published September 5, 2017
  • EVERYDAY UROLOGY: Bone Metastases and Mortality in Prostate Cancer, Can We Be Doing More?- Full text article

    Published in Everyday Urology - Oncology Insights: Volume 3, Issue 3
    Prostate cancer is the most common malignancy among US men, with an estimated annual incidence of 180,890, accounting for one in five new cancer cases in men [1]. The second-most common cause of cancer death in US men, prostate cancer is expected to claim the lives of 26,120 men in this country in 2016 [1]. For men with castration-resistant prostate cancer (CRPC), median survival ranges from nine to 34 months, depending upon numerous factors, including but not limited to, the presence of metastases, the location and  volume of metastases, the presence of co-morbidities, the degree of acknowledged and interrogated symptomatology, etc.  [2]. 
    Published November 16, 2016
  • FDA approves new drug for advanced prostate cancer

    BERKELEY, CA USA (Press Release) - May 15, 2013 -

    Xofigo approved three months ahead of schedule under priority review program

    Published May 15, 2013
  • Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

    Background: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label Phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after docetaxel (Phase I), and after docetaxel and abiraterone (Phase II) (NCT01511536).
    Published November 1, 2016

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.